Published in Malar J on June 28, 2007
New insights into acquisition, boosting, and longevity of immunity to malaria in pregnant women. J Infect Dis (2012) 2.52
Using serological measures to monitor changes in malaria transmission in Vanuatu. Malar J (2010) 2.47
Duration of naturally acquired antibody responses to blood-stage Plasmodium falciparum is age dependent and antigen specific. Infect Immun (2008) 2.18
The Plasmodium falciparum-specific human memory B cell compartment expands gradually with repeated malaria infections. PLoS Pathog (2010) 2.03
The contribution of Plasmodium chabaudi to our understanding of malaria. Trends Parasitol (2011) 1.99
Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development. Sci Transl Med (2009) 1.95
Analysis of immunity to febrile malaria in children that distinguishes immunity from lack of exposure. Infect Immun (2009) 1.79
Associations between Burkitt lymphoma among children in Malawi and infection with HIV, EBV and malaria: results from a case-control study. PLoS One (2008) 1.70
Phase 1 study of a combination AMA1 blood stage malaria vaccine in Malian children. PLoS One (2008) 1.54
Acquisition of growth-inhibitory antibodies against blood-stage Plasmodium falciparum. PLoS One (2008) 1.53
Malaria immunity in man and mosquito: insights into unsolved mysteries of a deadly infectious disease. Annu Rev Immunol (2014) 1.38
World Malaria Day 2009: what malaria knows about the immune system that immunologists still do not. J Immunol (2009) 1.32
Sero-epidemiological evaluation of changes in Plasmodium falciparum and Plasmodium vivax transmission patterns over the rainy season in Cambodia. Malar J (2012) 1.27
A positive correlation between atypical memory B cells and Plasmodium falciparum transmission intensity in cross-sectional studies in Peru and Mali. PLoS One (2011) 1.21
Measurement of Plasmodium falciparum transmission intensity using serological cohort data from Indonesian schoolchildren. Malar J (2013) 1.20
What you see is not what you get: implications of the brevity of antibody responses to malaria antigens and transmission heterogeneity in longitudinal studies of malaria immunity. Malar J (2009) 1.18
Functional memory B cells and long-lived plasma cells are generated after a single Plasmodium chabaudi infection in mice. PLoS Pathog (2009) 1.15
The breadth, but not the magnitude, of circulating memory B cell responses to P. falciparum increases with age/exposure in an area of low transmission. PLoS One (2011) 1.14
Novel serologic biomarkers provide accurate estimates of recent Plasmodium falciparum exposure for individuals and communities. Proc Natl Acad Sci U S A (2015) 1.13
New antigens for a multicomponent blood-stage malaria vaccine. Sci Transl Med (2014) 1.11
Estimation of recent and long-term malaria transmission in a population by antibody testing to multiple Plasmodium falciparum antigens. J Infect Dis (2014) 1.07
The dynamics of naturally acquired immune responses to Plasmodium falciparum sexual stage antigens Pfs230 & Pfs48/45 in a low endemic area in Tanzania. PLoS One (2010) 1.06
Young lives lost as B cells falter: what we are learning about antibody responses in malaria. J Immunol (2013) 1.02
Opsonising antibodies to P. falciparum merozoites associated with immunity to clinical malaria. PLoS One (2013) 1.01
Temporal stability of naturally acquired immunity to Merozoite Surface Protein-1 in Kenyan adults. Malar J (2009) 1.00
Breadth of anti-merozoite antibody responses is associated with the genetic diversity of asymptomatic Plasmodium falciparum infections and protection against clinical malaria. Clin Infect Dis (2013) 0.99
Plasmodium falciparum malaria in the Peruvian Amazon, a region of low transmission, is associated with immunologic memory. Infect Immun (2012) 0.99
Hepatosplenomegaly is associated with low regulatory and Th2 responses to schistosome antigens in childhood schistosomiasis and malaria coinfection. Infect Immun (2008) 0.99
Effect of treating Schistosoma haematobium infection on Plasmodium falciparum-specific antibody responses. BMC Infect Dis (2008) 0.98
Allele-specific antibodies to Plasmodium falciparum merozoite surface protein-2 and protection against clinical malaria. Parasite Immunol (2010) 0.94
Malaria-associated atypical memory B cells exhibit markedly reduced B cell receptor signaling and effector function. Elife (2015) 0.94
Research priorities for the development and implementation of serological tools for malaria surveillance. F1000Prime Rep (2014) 0.94
Clearance of asymptomatic P. falciparum Infections Interacts with the number of clones to predict the risk of subsequent malaria in Kenyan children. PLoS One (2011) 0.93
Standardization and validation of a cytometric bead assay to assess antibodies to multiple Plasmodium falciparum recombinant antigens. Malar J (2012) 0.90
Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection. Immunology (2014) 0.90
Assessment of exposure to Plasmodium falciparum transmission in a low endemicity area by using multiplex fluorescent microsphere-based serological assays. Parasit Vectors (2011) 0.90
The effect of daily co-trimoxazole prophylaxis on natural development of antibody-mediated immunity against P. falciparum malaria infection in HIV-exposed uninfected Malawian children. PLoS One (2015) 0.88
Suppression of circulating IgD+CD27+ memory B cells in infants living in a malaria-endemic region of Kenya. Malar J (2011) 0.86
Changes in B Cell Populations and Merozoite Surface Protein-1-Specific Memory B Cell Responses after Prolonged Absence of Detectable P. falciparum Infection. PLoS One (2013) 0.85
Toward a surrogate marker of malaria exposure: modeling longitudinal antibody measurements under outbreak conditions. PLoS One (2011) 0.85
Malaria hotspots defined by clinical malaria, asymptomatic carriage, PCR and vector numbers in a low transmission area on the Kenyan Coast. Malar J (2016) 0.85
High antibody responses against Plasmodium falciparum in immigrants after extended periods of interrupted exposure to malaria. PLoS One (2013) 0.84
Biosignatures of Exposure/Transmission and Immunity. Am J Trop Med Hyg (2015) 0.84
The design and statistical power of treatment re-infection studies of the association between pre-erythrocytic immunity and infection with Plasmodium falciparum. Malar J (2013) 0.84
Sample size and power calculations for detecting changes in malaria transmission using antibody seroconversion rate. Malar J (2015) 0.83
Correlates of HIV and malaria co-infection in Southern India. Malar J (2012) 0.83
Targets and Mechanisms Associated with Protection from Severe Plasmodium falciparum Malaria in Kenyan Children. Infect Immun (2016) 0.83
Asymptomatic Multiclonal Plasmodium falciparum Infections Carried Through the Dry Season Predict Protection Against Subsequent Clinical Malaria. J Infect Dis (2015) 0.82
Relationship between malaria incidence and IgG levels to Plasmodium falciparum merozoite antigens in Malian children: impact of hemoglobins S and C. PLoS One (2013) 0.82
B-cell responses to pregnancy-restricted and -unrestricted Plasmodium falciparum erythrocyte membrane protein 1 antigens in Ghanaian women naturally exposed to malaria parasites. Infect Immun (2014) 0.82
Developmental allometry and paediatric malaria. Malar J (2012) 0.82
Quantitative PCR evaluation of cellular immune responses in Kenyan children vaccinated with a candidate malaria vaccine. PLoS One (2009) 0.81
Estimating malaria transmission intensity from Plasmodium falciparum serological data using antibody density models. Malar J (2016) 0.80
High and Heterogeneous Prevalence of Asymptomatic and Sub-microscopic Malaria Infections on Islands in Lake Victoria, Kenya. Sci Rep (2016) 0.80
Malaria and immunity during pregnancy and postpartum: a tale of two species. Parasitology (2015) 0.80
Serological markers to measure recent changes in malaria at population level in Cambodia. Malar J (2016) 0.78
Kinetics of humoral and memory B cell response induced by the Plasmodium falciparum 19-kilodalton merozoite surface protein 1 in mice. Infect Immun (2011) 0.78
Impact of acute malaria on pre-existing antibodies to viral and vaccine antigens in mice and humans. PLoS One (2015) 0.77
Protection of Malian children from clinical malaria is associated with recognition of multiple antigens. Malar J (2015) 0.77
Type I Interferons Induce T Regulatory 1 Responses and Restrict Humoral Immunity during Experimental Malaria. PLoS Pathog (2016) 0.77
The effect of declining exposure on T cell-mediated immunity to Plasmodium falciparum - an epidemiological "natural experiment". BMC Med (2016) 0.76
Novel flow cytometry technique for detection of Plasmodium falciparum specific B-cells in humans: increased levels of specific B-cells in ongoing infection. Malar J (2015) 0.76
Cutting Edge: IL-10 Is Essential for the Generation of Germinal Center B Cell Responses and Anti-Plasmodium Humoral Immunity. J Immunol (2016) 0.75
Longevity of Genotype-Specific Immune Responses to Plasmodium falciparum Merozoite Surface Protein 1 in Kenyan Children from Regions of Different Malaria Transmission Intensity. Am J Trop Med Hyg (2016) 0.75
Merozoite Antigens of Plasmodium falciparum Elicit Strain-Transcending Opsonizing Immunity. Infect Immun (2016) 0.75
Cord blood IgG and the risk of severe Plasmodium falciparum malaria in the first year of life. Int J Parasitol (2016) 0.75
Differential requirement for cathepsin D for processing of the full length and C-terminal fragment of the malaria antigen MSP1. PLoS One (2011) 0.75
Parasite Specific Antibody Increase Induced by an Episode of Acute P. falciparum Uncomplicated Malaria. PLoS One (2015) 0.75
A longitudinal cohort study of malaria exposure and changing serostatus in a malaria endemic area of rural Tanzania. Malar J (2017) 0.75
Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster. Trans R Soc Trop Med Hyg (2000) 22.12
Maintenance of serological memory by polyclonal activation of human memory B cells. Science (2002) 8.75
Humoral immunity due to long-lived plasma cells. Immunity (1998) 6.35
Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria. Vaccine (2004) 3.51
Metabolic properties of IgG subclasses in man. J Clin Invest (1970) 3.48
A longitudinal study of type-specific antibody responses to Plasmodium falciparum merozoite surface protein-1 in an area of unstable malaria in Sudan. J Immunol (1998) 2.94
Possible role of a B-cell mitogen in hypergammaglobulinaemia in malaria and trypanosomiasis. Lancet (1974) 2.83
Expression of the 19-kilodalton carboxy-terminal fragment of the Plasmodium falciparum merozoite surface protein-1 in Escherichia coli as a correctly folded protein. Mol Biochem Parasitol (1994) 2.71
Impairment of the immune response to vaccination after acute malaria. Lancet (1978) 2.39
Purification, characterization, and immunogenicity of the refolded ectodomain of the Plasmodium falciparum apical membrane antigen 1 expressed in Escherichia coli. Infect Immun (2002) 2.37
Long-lived plasma cells: a mechanism for maintaining persistent antibody production. Curr Opin Immunol (1998) 2.10
The role of bone marrow-derived stromal cells in the maintenance of plasma cell longevity. J Immunol (2002) 1.99
High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya. Vaccine (2005) 1.89
Intrinsic constraint on plasmablast growth and extrinsic limits of plasma cell survival. J Exp Med (2000) 1.87
Disorders of immunoglobulin metabolism. N Engl J Med (1969) 1.69
Humoral immunity and long-lived plasma cells. Curr Opin Immunol (2002) 1.63
Protective long-term antibody memory by antigen-driven and T help-dependent differentiation of long-lived memory B cells to short-lived plasma cells independent of secondary lymphoid organs. Proc Natl Acad Sci U S A (2000) 1.57
Human antibody response to the major merozoite surface antigen of Plasmodium falciparum is strain specific and short-lived. Infect Immun (1991) 1.55
Loss of red blood cell-complement regulatory proteins and increased levels of circulating immune complexes are associated with severe malarial anemia. J Infect Dis (2003) 1.41
A model for sequestration of the transmission stages of Plasmodium falciparum: adhesion of gametocyte-infected erythrocytes to human bone marrow cells. Infect Immun (2000) 1.36
Longevity of naturally acquired antibody responses to the N- and C-terminal regions of Plasmodium vivax merozoite surface protein 1. Am J Trop Med Hyg (1999) 1.35
Molecular mechanisms of measles virus persistence. Virus Res (2005) 1.32
Relationship between humoral response to Plasmodium falciparum merozoite surface antigen-2 and malaria morbidity in a highly endemic area of Papua New Guinea. Am J Trop Med Hyg (1994) 1.30
Decline in meningococcal antibody levels in African children 5 years after vaccination and the lack of an effect of booster immunization. J Infect Dis (1993) 1.14
Modelling antibody response to measles vaccine and subsequent waning of immunity in a low exposure population. Vaccine (2000) 1.11
Baculovirus-mediated expression of Plasmodium falciparum erythrocyte binding antigen 175 polypeptides and their recognition by human antibodies. Infect Immun (1997) 1.07
A longitudinal study of human antibody responses to Plasmodium falciparum rhoptry-associated protein 1 in a region of seasonal and unstable malaria transmission. Infect Immun (1999) 1.03
Persistence of vaccine-induced antibody to measles 26-33 years after vaccination. J Infect Dis (2004) 0.99
Antibody responses to Rhoptry-Associated Protein-1 (RAP-1) of Plasmodium falciparum parasites in humans from areas of different malaria endemicity. Parasite Immunol (1997) 0.98
Acquired antibody levels to Plasmodium falciparum merozoite surface antigen 1 in residents of a highly endemic area of Papua New Guinea. Trans R Soc Trop Med Hyg (1996) 0.97
Distribution of immunoglobulin isotypes in the nonspecific B-cell response induced by infection with Plasmodium chabaudi adami and Plasmodium yoelii. Cell Immunol (1985) 0.93
Immunity to diphtheria and tetanus in England and Wales. Vaccine (2000) 0.92
Soluble immune complex triggering of a respiratory burst in macrophages: the role of complex aggregation at the phagocyte surface. Eur J Immunol (1987) 0.83
Bacteremia among children admitted to a rural hospital in Kenya. N Engl J Med (2005) 13.27
A large focus of naturally acquired Plasmodium knowlesi infections in human beings. Lancet (2004) 12.21
First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med (2011) 10.79
The pathogenic basis of malaria. Nature (2002) 10.44
Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening. Clin Infect Dis (2008) 9.87
Changes in malaria indices between 1999 and 2007 in The Gambia: a retrospective analysis. Lancet (2008) 9.05
Effect of a fall in malaria transmission on morbidity and mortality in Kilifi, Kenya. Lancet (2008) 8.50
The decline in paediatric malaria admissions on the coast of Kenya. Malar J (2007) 7.45
Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med (2008) 7.28
A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med (2012) 6.64
The consequences of reducing transmission of Plasmodium falciparum in Africa. Adv Parasitol (2002) 6.01
Immunity to malaria: more questions than answers. Nat Immunol (2008) 5.71
Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nat Genet (2013) 5.22
Evidence for the involvement of VAR2CSA in pregnancy-associated malaria. J Exp Med (2004) 4.76
Bacteraemia in Kenyan children with sickle-cell anaemia: a retrospective cohort and case-control study. Lancet (2009) 4.76
Case definitions of clinical malaria under different transmission conditions in Kilifi District, Kenya. J Infect Dis (2005) 4.44
Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing. Nature (2012) 4.37
Genome-wide and fine-resolution association analysis of malaria in West Africa. Nat Genet (2009) 4.30
A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat Genet (2007) 4.23
Negative epistasis between the malaria-protective effects of alpha+-thalassemia and the sickle cell trait. Nat Genet (2005) 4.22
Epidemic multiple drug resistant Salmonella Typhimurium causing invasive disease in sub-Saharan Africa have a distinct genotype. Genome Res (2009) 3.99
Relation between falciparum malaria and bacteraemia in Kenyan children: a population-based, case-control study and a longitudinal study. Lancet (2011) 3.78
Stable and unstable malaria hotspots in longitudinal cohort studies in Kenya. PLoS Med (2010) 3.78
Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. Infect Immun (2008) 3.51
Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria. Vaccine (2004) 3.51
Effect of two different house screening interventions on exposure to malaria vectors and on anaemia in children in The Gambia: a randomised controlled trial. Lancet (2009) 3.45
Use of clinical syndromes to target antibiotic prescribing in seriously ill children in malaria endemic area: observational study. BMJ (2005) 3.34
CISH and susceptibility to infectious diseases. N Engl J Med (2010) 3.31
Burden, features, and outcome of neurological involvement in acute falciparum malaria in Kenyan children. JAMA (2007) 3.29
Variant surface antigen-specific IgG and protection against clinical consequences of pregnancy-associated Plasmodium falciparum malaria. Lancet (2004) 3.25
A field trial to assess a blood-stage malaria vaccine. N Engl J Med (2011) 3.20
Sickle cell trait and the risk of Plasmodium falciparum malaria and other childhood diseases. J Infect Dis (2005) 3.12
HIV infection, malnutrition, and invasive bacterial infection among children with severe malaria. Clin Infect Dis (2009) 2.80
Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. Lancet Infect Dis (2011) 2.79
Plasmodium falciparum merozoite surface protein 3 is a target of allele-specific immunity and alleles are maintained by natural selection. J Infect Dis (2006) 2.75
Clinical features and pathogenesis of severe malaria. Trends Parasitol (2004) 2.73
Clinical research in resource-limited settings: enhancing research capacity and working together to make trials less complicated. PLoS Negl Trop Dis (2010) 2.68
Profile: The Kilifi Health and Demographic Surveillance System (KHDSS). Int J Epidemiol (2012) 2.64
Quantitative detection of Plasmodium falciparum DNA in saliva, blood, and urine. J Infect Dis (2009) 2.64
Transient cross-reactive immune responses can orchestrate antigenic variation in malaria. Nature (2004) 2.56
Risk factors for house-entry by malaria vectors in a rural town and satellite villages in The Gambia. Malar J (2008) 2.51
Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. PLoS One (2009) 2.49
Heritability of malaria in Africa. PLoS Med (2005) 2.49
Continued decline of malaria in The Gambia with implications for elimination. PLoS One (2010) 2.47
Clinical algorithms for malaria diagnosis lack utility among people of different age groups. Trop Med Int Health (2005) 2.46
Plasmodium knowlesi: reservoir hosts and tracking the emergence in humans and macaques. PLoS Pathog (2011) 2.45
Malaria in Africa: progress and prospects in the decade since the Abuja Declaration. Lancet (2010) 2.41
Purification, characterization, and immunogenicity of the refolded ectodomain of the Plasmodium falciparum apical membrane antigen 1 expressed in Escherichia coli. Infect Immun (2002) 2.37
In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1. Antimicrob Agents Chemother (2009) 2.36
Iron deficiency and malaria among children living on the coast of Kenya. J Infect Dis (2004) 2.34
A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS Clin Trials (2006) 2.33
Relationship between exposure, clinical malaria, and age in an area of changing transmission intensity. Am J Trop Med Hyg (2008) 2.29
Isolation of viable Plasmodium falciparum merozoites to define erythrocyte invasion events and advance vaccine and drug development. Proc Natl Acad Sci U S A (2010) 2.25
Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure. N Engl J Med (2013) 2.24
Profiling the antibody immune response against blood stage malaria vaccine candidates. Clin Chem (2007) 2.23
Defining childhood severe falciparum malaria for intervention studies. PLoS Med (2007) 2.22
Duration of naturally acquired antibody responses to blood-stage Plasmodium falciparum is age dependent and antigen specific. Infect Immun (2008) 2.18
Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine (2005) 2.18
Structural basis of antigenic escape of a malaria vaccine candidate. Proc Natl Acad Sci U S A (2007) 2.15
Plasmodium falciparum variant surface antigen expression patterns during malaria. PLoS Pathog (2005) 2.13
The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. Nat Commun (2011) 2.11
An immune basis for malaria protection by the sickle cell trait. PLoS Med (2005) 2.08
Blood group O protects against severe Plasmodium falciparum malaria through the mechanism of reduced rosetting. Proc Natl Acad Sci U S A (2007) 2.07
Invasion-inhibitory antibodies inhibit proteolytic processing of apical membrane antigen 1 of Plasmodium falciparum merozoites. Proc Natl Acad Sci U S A (2003) 2.01
Declining responsiveness of Plasmodium falciparum infections to artemisinin-based combination treatments on the Kenyan coast. PLoS One (2011) 2.00
Cerebral malaria: mechanisms of brain injury and strategies for improved neurocognitive outcome. Pediatr Res (2010) 1.98
Antibodies to Plasmodium falciparum antigens predict a higher risk of malaria but protection from symptoms once parasitemic. J Infect Dis (2011) 1.98
Variation in use of erythrocyte invasion pathways by Plasmodium falciparum mediates evasion of human inhibitory antibodies. J Clin Invest (2008) 1.96
The role of antibodies to Plasmodium falciparum-infected-erythrocyte surface antigens in naturally acquired immunity to malaria. Trends Microbiol (2002) 1.95
Maternal HIV infection and placental malaria reduce transplacental antibody transfer and tetanus antibody levels in newborns in Kenya. J Infect Dis (2007) 1.94
The effects of untreated bednets on malaria infection and morbidity on the Kenyan coast. Trans R Soc Trop Med Hyg (2004) 1.91
Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trial. PLoS One (2008) 1.90
Malaria and nutritional status in children living on the coast of Kenya. Am J Clin Nutr (2004) 1.90
The role of the district hospital in child survival at the Kenyan Coast. Afr J Health Sci (1994) 1.90
High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya. Vaccine (2005) 1.89
Chloroquine resistance before and after its withdrawal in Kenya. Malar J (2009) 1.88
Hypothetical performance of syndrome-based management of acute paediatric admissions of children aged more than 60 days in a Kenyan district hospital. Bull World Health Organ (2003) 1.87
Plasmodium falciparum var gene expression is modified by host immunity. Proc Natl Acad Sci U S A (2009) 1.86
Erythrocyte invasion phenotypes of Plasmodium falciparum in The Gambia. Infect Immun (2003) 1.85
Allele frequency-based analyses robustly map sequence sites under balancing selection in a malaria vaccine candidate antigen. Genetics (2003) 1.82
Distinct roles for FOXP3 and FOXP3 CD4 T cells in regulating cellular immunity to uncomplicated and severe Plasmodium falciparum malaria. PLoS Pathog (2009) 1.81
Analysis of immunity to febrile malaria in children that distinguishes immunity from lack of exposure. Infect Immun (2009) 1.79
Development and optimization of high-throughput methods to measure Plasmodium falciparum-specific growth inhibitory antibodies. J Clin Microbiol (2006) 1.78
Serum IgG3 to the Plasmodium falciparum merozoite surface protein 2 is strongly associated with a reduced prospective risk of malaria. Parasite Immunol (2003) 1.77
Anopheles gambiae complex along The Gambia river, with particular reference to the molecular forms of An. gambiae s.s. Malar J (2008) 1.76
Malaria as a cause of morbidity and mortality in children with homozygous sickle cell disease on the coast of Kenya. Clin Infect Dis (2009) 1.74
The effect of alpha+-thalassaemia on the incidence of malaria and other diseases in children living on the coast of Kenya. PLoS Med (2006) 1.73
The changing limits and incidence of malaria in Africa: 1939-2009. Adv Parasitol (2012) 1.72
A decline in the incidence of invasive non-typhoidal Salmonella infection in The Gambia temporally associated with a decline in malaria infection. PLoS One (2010) 1.72
Common variation in the ABO glycosyltransferase is associated with susceptibility to severe Plasmodium falciparum malaria. Hum Mol Genet (2007) 1.72
Mortality in sickle cell anemia in Africa: a prospective cohort study in Tanzania. PLoS One (2011) 1.71
Opsonic phagocytosis of Plasmodium falciparum merozoites: mechanism in human immunity and a correlate of protection against malaria. BMC Med (2014) 1.71